

Dab/Tram (dabrafenib and trametinib) COMBI-AD

PRELIMINARY SCORE

CURATIVE

NEB

NON-CURATIVE

ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Dab/Tram (dabrafenib and trametinib) COMBI-AD

SCORE

CURATIVE

NEB

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection

Experimental Arm: Dab/Tram (dabrafenib and trametinib)

Control Arm: Placebo



